Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DNDN Halted, reportedly FDA Approved
Look for some rotation into POZN bening she's next on many radars!
DNDN HALTED
HALTED
DNDN approval reported, just went past my screen, no story yet
DNDN approval reported, got headline but no story yet
DNDN pop!!! Appvl reported?!
got a headline but no story
PT, what do you like about YRCW? TIA
They're getting pretty beat up following:
-Short interest rose 252.9 percent to 55.9 million shares.
-The unexpected departure of the company's president, Tim Wicks, in mid-April rattled investors who saw the move as a blow to the still-struggling trucking giant and a sign of continuing instability. <ReutersLink ID='ID:nN13253495' /> Wicks had helped YRC navigate several complicated restructuring moves
-struggling to avoid bankruptcy, agreed to a significant equity dilution to win Teamsters concessions last year.
-float = 1.02 Billion
It caught my eye after wick's departure but am still looking for some catalyst to propell a reversal.
Thanks -
S
lol, posc news flood reminds me of the old barrage of gnbt pr's...
-We're goin to the moon...
-We're really going...
-It's almost time to go...
-Gonna make it....
-We want to tell you that we'll be holding a press conf. to tell you we're going to the moon...
-Almost ready...
-Time to head to the lauchpad...
anyway I hope those playing it make $$$
GL
S
fwiw, keep the eyes on the prize
The DD on this one is solid. We really don't know when the FDA/POZN will announce results and I give it a 50/50 they do it per schedule. Watching every tick will wear you out with all the flippers/amateurs/mm games in the event they get discouraged/impatient and bail
glta
S
Other NVAX DD: They are recruiting for a Government Contract Accountant and CMO (jobs posted on their web site). The acctg position most intriguing
Fm seekingalpha post and http://www.novavax.com/go.cfm?do=Page.View&pid=19
"Related to BARDA award? I suspect so....they wouldn't be recruiting for this position right now otherwise,imo
--
We are seeking a Government Contract Accountant to join our Finance & Accounting Department in Rockville, MD.
Candidate is responsible for accounting, estimating, invoices, reporting, and CAS/FAR compliance for U.S. Federal Government contracts.
Responsibilities include but are not limited to:
? Prepare Bid and Provisional Indirect Rates
? Prepare forward pricing
? Manage compliant project cost accounting system
? Prepare/Review cost proposals and contract modifications
? Review monthly invoices
? Generate program status reports and forecasts
? Prepare annual Incurred Cost Submission
? Provide interface and support for government audits
? Setup and management, to include processing contract and task modification, updating contract data, handing requests for data and ensuring contract compliance
? Billings, revenue recognition and collections
? Work with project manager to ensure contract cost accuracy
? Work with project manager on ETC analysis
? Preparation of monthly JSR’s
? Provide estimate of cash receipts for cash flow forecasting
? Verify subcontractors and vendors are paid per contracted arrangements
? Analyze unbilled billed AR
? Monthly GL Reconciliation
? Assist with Accounts Payable "
NVAX - Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
8:00 am ET 04/29/2010- PR Newswire
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
In a double-blind, active-controlled Phase II study of 480 randomized subjects, the safety, tolerability and immunogenicity of a single 15 microgram dose or 60 microgram dose (per strain) of trivalent influenza VLP was compared to a dose of a commercially available inactivated trivalent influenza vaccine (TIV). The primary immunogenicity measure in the study was hemagglutination inhibition (HAI) antibody response induced by the vaccine 21 days after immunization. At both the high (60 microgram) and low (15 microgram) dose, the VLP vaccine showed no significant increase in severe local or systemic adverse events.
While the study was not powered to obtain definitive differences in immunogenicity between VLP doses or establish non-inferiority between VLPs and TIV, a preliminary analysis of immunogenicity results showed that the 60 microgram dose of trivalent VLP vaccine induced a statistically significant higher seroconversion rate than TIV against one of the three 2009-2010 strains of seasonal influenza virus and showed no statistically significant difference from TIV in the seroconversion rate against the other two strains. The 15 microgram dose of trivalent VLP vaccine did not induce significantly different seroconversion rates than TIV for two of the three strains, but induced a significantly lower seroconversion rate compared to TIV against one of the strains.
These immunogenicity responses observed in the VLP vaccine groups will be used to guide the selection of a dose most likely to meet or exceed the U.S. and European regulatory guidelines for immunogenicity and safety criteria for licensure of the vaccine for older adults.
Dr. Rahul Singhvi, President and CEO of Novavax, stated: "We are pleased to see that both doses of VLP vaccine were well tolerated and immunogenic in older adults, which was a key question for this trial. The finding that a higher dose of VLP vaccine could be more immunogenic in this population is particularly important since there is a significant medical need for a better vaccine for older adults. These data show that our recombinant, VLP-vaccine technology affords great flexibility in using dose as a means to improve the possible effectiveness of the vaccine. The data from this clinical trial and from our recent Phase II influenza vaccine study in healthy younger adults suggest that our trivalent influenza vaccine may be effective in a broad range of subjects. Taken together, the findings from these studies are encouraging and will be useful for planning further clinical testing of our trivalent VLP influenza vaccine."
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
NVAX - Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
8:00 am ET 04/29/2010- PR Newswire
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
In a double-blind, active-controlled Phase II study of 480 randomized subjects, the safety, tolerability and immunogenicity of a single 15 microgram dose or 60 microgram dose (per strain) of trivalent influenza VLP was compared to a dose of a commercially available inactivated trivalent influenza vaccine (TIV). The primary immunogenicity measure in the study was hemagglutination inhibition (HAI) antibody response induced by the vaccine 21 days after immunization. At both the high (60 microgram) and low (15 microgram) dose, the VLP vaccine showed no significant increase in severe local or systemic adverse events.
While the study was not powered to obtain definitive differences in immunogenicity between VLP doses or establish non-inferiority between VLPs and TIV, a preliminary analysis of immunogenicity results showed that the 60 microgram dose of trivalent VLP vaccine induced a statistically significant higher seroconversion rate than TIV against one of the three 2009-2010 strains of seasonal influenza virus and showed no statistically significant difference from TIV in the seroconversion rate against the other two strains. The 15 microgram dose of trivalent VLP vaccine did not induce significantly different seroconversion rates than TIV for two of the three strains, but induced a significantly lower seroconversion rate compared to TIV against one of the strains.
These immunogenicity responses observed in the VLP vaccine groups will be used to guide the selection of a dose most likely to meet or exceed the U.S. and European regulatory guidelines for immunogenicity and safety criteria for licensure of the vaccine for older adults.
Dr. Rahul Singhvi, President and CEO of Novavax, stated: "We are pleased to see that both doses of VLP vaccine were well tolerated and immunogenic in older adults, which was a key question for this trial. The finding that a higher dose of VLP vaccine could be more immunogenic in this population is particularly important since there is a significant medical need for a better vaccine for older adults. These data show that our recombinant, VLP-vaccine technology affords great flexibility in using dose as a means to improve the possible effectiveness of the vaccine. The data from this clinical trial and from our recent Phase II influenza vaccine study in healthy younger adults suggest that our trivalent influenza vaccine may be effective in a broad range of subjects. Taken together, the findings from these studies are encouraging and will be useful for planning further clinical testing of our trivalent VLP influenza vaccine."
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
About Novavax
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. In 2009, Novavax launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website
NVAX - Novavax's Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
8:00 am ET 04/29/2010- PR Newswire
ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) reported today that its trivalent seasonal influenza virus-like-particle (VLP)-based vaccine candidate was safe and immunogenic against the 2009-2010 seasonal influenza virus strains in older adults 60 years or higher in age.
In a double-blind, active-controlled Phase II study of 480 randomized subjects, the safety, tolerability and immunogenicity of a single 15 microgram dose or 60 microgram dose (per strain) of trivalent influenza VLP was compared to a dose of a commercially available inactivated trivalent influenza vaccine (TIV). The primary immunogenicity measure in the study was hemagglutination inhibition (HAI) antibody response induced by the vaccine 21 days after immunization. At both the high (60 microgram) and low (15 microgram) dose, the VLP vaccine showed no significant increase in severe local or systemic adverse events.
While the study was not powered to obtain definitive differences in immunogenicity between VLP doses or establish non-inferiority between VLPs and TIV, a preliminary analysis of immunogenicity results showed that the 60 microgram dose of trivalent VLP vaccine induced a statistically significant higher seroconversion rate than TIV against one of the three 2009-2010 strains of seasonal influenza virus and showed no statistically significant difference from TIV in the seroconversion rate against the other two strains. The 15 microgram dose of trivalent VLP vaccine did not induce significantly different seroconversion rates than TIV for two of the three strains, but induced a significantly lower seroconversion rate compared to TIV against one of the strains.
These immunogenicity responses observed in the VLP vaccine groups will be used to guide the selection of a dose most likely to meet or exceed the U.S. and European regulatory guidelines for immunogenicity and safety criteria for licensure of the vaccine for older adults.
Dr. Rahul Singhvi, President and CEO of Novavax, stated: "We are pleased to see that both doses of VLP vaccine were well tolerated and immunogenic in older adults, which was a key question for this trial. The finding that a higher dose of VLP vaccine could be more immunogenic in this population is particularly important since there is a significant medical need for a better vaccine for older adults. These data show that our recombinant, VLP-vaccine technology affords great flexibility in using dose as a means to improve the possible effectiveness of the vaccine. The data from this clinical trial and from our recent Phase II influenza vaccine study in healthy younger adults suggest that our trivalent influenza vaccine may be effective in a broad range of subjects. Taken together, the findings from these studies are encouraging and will be useful for planning further clinical testing of our trivalent VLP influenza vaccine."
About VLPs
Virus-like particles (VLPs) mimic the external structure of viruses but lack the live genetic material that causes viral replication and infection. VLPs can be designed quickly to match individual viral strains and be produced efficiently using portable cell-culture technology. Novavax's VLP-based vaccine candidates are produced more rapidly than egg-based vaccines by using proprietary, portable, recombinant cell-culture technology.
About Novavax
Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based, recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. In 2009, Novavax launched a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website
MNKD spike on 1/2M sh
MNKD spike
NVAX, nice call on ppl, Mr.D ... still going
NVAX trying to breakout has next speedbump abt 3.
OT: and GS is played by Jafar or Scar, Congress is Capt.Hook's crew from "Hook"
http://www.ultimatedisney.com/countdown4/index3.html
POSC careful and gl, spitting out worthless news pieces to gen hype a red flag at this desk
SURG - big settlement news and conf call announced for today should play into the cc
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49522955
SURG - Announces Distribution Deal with Alcon (ACL); Settles Litigation; To Receive $32M For the Rights
5:25 pm ET 04/27/2010 - StreetInsider
Synergetics USA, Inc., (Nasdaq: SURG) announced today the signing of a pair of agreements with Alcon Laboratories, Inc. (NYSE: ACL) granting Alcon a license to sell certain products manufactured by Synergetics for worldwide distribution on a co-exclusive basis throughout the extensive Alcon network and covering the terms of supply of such products to Alcon by Synergetics. The agreements also settle all litigation between Synergetics and Alcon.
As provided by the Settlement & License Agreement and Supply Agreement, Alcon will pay Synergetics approximately $32 million for the right to sell certain Synergetics' patented products worldwide and to settle all pending litigation between the companies. These Agreements also provide for the resolution of any future disputes through a well-defined mediation process.
"We are pleased to be able to enter into a long term business relationship with Alcon, and settle all litigation between the companies," commented Robert Dick, Chairman of the Synergetics' Board. Bob went on to say, "Synergetics welcomes the opportunity to work with Alcon to provide ophthalmic surgeons throughout the world with select instruments
Synergetics USA Announces Conference Call
8:49 am ET 04/28/2010- PR Newswire
O'FALLON, Mo., April 28 /PRNewswire-FirstCall/ -- Synergetics USA, Inc., (Nasdaq: SURG) will provide an online, real-time webcast and broadcast of its conference call on Wednesday, April 28, 2010, covering the settlement and license agreement with Alcon.
The live broadcast of Synergetics USA conference call will be available on-line at: http://www.synergeticsusa.com on April 28, 2010, beginning at 12:00 p.m. (Eastern Time). The online replay will follow immediately and continue for 30 days. To hear the Company's conference call live, dial 888-811-5448, confirmation code 7150418. A replay will be available from 2:00 p.m. (Eastern Time) on April 28 until 11:00 p.m. (Eastern Time) on May 5. To listen to the playback, call 7194570820, confirmation code 7150418.
SQNM upgraded w/ PT $10
Shares of the often-momentous Sequenom have jumped more than 4% in the pre-market trading session as we are hearing that an analyst at Global Hunter Securities has upgraded the stock from Neutral to Buy and also set a $10 price target.
SQNM perky in pm...upgraded w/ $10 PT
"Shares of the often-momentous Sequenom have jumped more than 4% in the pre-market trading session as we are hearing that an analyst at Global Hunter Securities has upgraded the stock from Neutral to Buy and also set a $10 price target."
MDCO - Medicines Co Q1 profit beats estimates
I'm watching for a reversal off support back to $8 after trading down in in ydays bad feta and olives selloff.
9:00 am ET 04/28/2010- Reuters
* Q1 EPS 18 cents vs est 16 cents
* Q1 revenue $102.1 mln vs est $110.3 mln
April 28 (Reuters) - Medicines Co <MDCO.O> posted a better-than-expected quarterly profit helped by lower operating expense.
First-quarter net income was $9.4 million, or 18 cents a share, compared with a net loss of $3.3 million, or 6 cents a share in the year-ago period. <ReutersLink ID='ID:nWNAB3106' />
Excluding special items, the company earned 24 cents a share.
Revenue rose 3 percent to $102.1 million.
Total operating expense fell 14 percent, with research and development expense decreasing 31 percent.
Analysts were expecting earnings of 16 cents a share, on revenue of $110.3 million, according to Thomson Reuters I/B/E/S.
U.S. sales of the company's anti-clotting drug Angiomax stayed almost flat, but international revenue from the drug rose 75 percent to $5.6 million.
Shares of the company closed at $7.65 Tuesday on Nasdaq.
DCTH breakout to new hi's, continues to defy gravity
NVAX - Lazard Capital Initiates Coverage with a Buy
8:35 am ET 04/28/2010- StreetInsider
Lazard Capital initiates coverage on Novavax, Inc. (NASDAQ: NVAX) with a Buy rating. PT $4.
NVAX - Lazard Capital Initiates Coverage with a Buy
Lazard Capital initiates coverage on Novavax, Inc. (NASDAQ: NVAX) with a Buy rating. PT $4.
NVAX - Lazard Capital Initiates Coverage with a Buy
8:35 am ET 04/28/2010- StreetInsider
Lazard Capital initiates coverage on Novavax, Inc. (NASDAQ: NVAX) with a Buy rating. PT $4.
Not a shock here and I've been told there's not even 1/2 a brain between oz's scarecrow and me. My only shock today came when getting my AARP invite in the mail, lol
Thoughts on Earnings...
This same discussion is from $heff's board:
"Posted by: kookiekook Date: Tuesday, April 27, 2010 3:35:03 PM
In reply to: barefootrunner who wrote msg# 27123 Post # of 27131
POZN quarterly estimate of earnings by "professional analysts" is as follows:
Number of estimates 5
High estimate -$0.13
Low estimate -$0.27
Mean estimate -$0.17
I believe Pozn will beat the -$0.17 consensus and come in at -$0.15 or -$0.14 based on increasing sales of Treximet"
DCTH testing yday HOD
DCTH testing yday HOD
SNSS almost a Mill. shares just ripped by on way to new HOD
SNSS almost a Mill. shares just ripped by on way to new HOD
Pozen, Inc. ( POZN) Short Interest
POZN
Pozen, Inc.NASDAQ-GM
Date Short Interest Avg Daily Share Volume Days To Cover
4/15/2010 2,808,219 626,278 4.483982
3/31/2010 1,892,697 467,341 4.049927
3/15/2010 1,582,282 118,617 13.339420
Read more: http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=POZN&selected=POZN#ixzz0mKQszp9P
It's ramped approach to 11.54/11.66 dayhi's earlier this month, prospect of new closing hi this month...I expect to see shorts cover as pps approaches each of those levels imho
GL
s
More interesting is the ramped approach to 11.54/11.66 dayhi's earlier this month, prospect of new closing hi this month and all in today's spoiled feta smelling market, lol
expect to see shorts cover as pps approaches each of those levels imho
glta
s
WOW! Don't know who's making GS look worse... not that the senate subcommitee has to try that hard but these guys fm GS are stepping all over their own cranks at just about every turn.
There have been only two...TWO, dos, a pair of yes/no questions answered directly and the senate panel is going to great lengths to ask just yes/no questions...along with refering to everything regarding a trade as a "bet"
I give, time to start the weekend after taking the bait and thinking this had something to do w/ large breasts and to then have to reread it twice to figure out that it also wasn't about changing lesbian classifications but "lesion classifications"... rofl
make mine a double
ABIO just lit up, news?